Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies ferumoxytol in the magnetic resonance imaging of pediatric patients with brain tumors. Magnetic resonance imaging using ferumoxytol may help in viewing a brain tumor and blood vessels in and around the tumor in a different way than the standard gadolinium-based contrast agent. Imaging with this experimental contrast agent may give doctors more information about tumor blood supply and the extent of the tumor itself.


Clinical Trial Description

PRIMARY OBJECTIVE: I. Testing the superiority of ferumoxytol-based steady state (SS)-cerebral blood volume (CBV) maps over gadolinium-based contrast agent (GBCA)-based dynamic susceptibility weighted (DSC)-CBV maps in visualizing pediatric brain tumor blood volume maps. SECONDARY OBJECTIVES: I. Correlation of relative cerebral blood volume (rCBV) with histology and genetic markers. II. Assessment of therapeutic response. III. Assessment of late ferumoxytol enhancement at various stages of disease. OUTLINE: Patients undergo magnetic resonance imaging (MRI) with GBCA per standard of care over 45-60 minutes and then receive ferumoxytol intravenously (IV) followed by MRI over 10 minutes on day 1. Patients may optionally undergo MRI over 30 minutes without any contrast agent on day 2. Each study visit consisting of 2 days may repeat no more frequently than 4 weeks for up to 5 study visits at different stages of the disease as determined by the investigator. After completion of study, patients are followed up at 2 and 6 weeks and then periodically for 5 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03234309
Study type Interventional
Source OHSU Knight Cancer Institute
Contact
Status Withdrawn
Phase Phase 2
Start date October 20, 2017
Completion date August 30, 2021

See also
  Status Clinical Trial Phase
Completed NCT00001972 - PET Scan of Brain Metabolism in Relation to Age and Disease N/A
Completed NCT02798406 - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Phase 2
Terminated NCT02855086 - Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery Phase 1/Phase 2
Terminated NCT00638963 - Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) Phase 2
Completed NCT00178295 - Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury N/A
Recruiting NCT04810871 - Surgical Resection of Latent Brain Tumors Prior to Recurrence N/A
Recruiting NCT02800486 - Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA Phase 2
Completed NCT01621295 - Assessing the Patient Experience in Cancer Care N/A
Completed NCT02964416 - Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Phase 4
Completed NCT00001574 - A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
Recruiting NCT02861898 - Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT00040573 - Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma. Phase 1/Phase 2
Active, not recruiting NCT04553757 - Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
Recruiting NCT02754544 - Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors N/A
Recruiting NCT03216148 - 18F-FET PET in Childhood Brain Tumours Phase 2
Completed NCT00001171 - Evaluation of Factors in Human Brain Tumors N/A
Withdrawn NCT01413438 - Bevacizumab With or Without Surgery for Adult Glioblastomas Phase 2
Not yet recruiting NCT05516485 - Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography N/A
Recruiting NCT02639325 - Tumor Related Epilepsy
Recruiting NCT02672995 - Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial Phase 1